Trial Profile

A retrospective, propensity score-matched cohort study of Belimumab in Patients with Systemic lupus erythematosus in the United States

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Systemic lupus erythematosus
Focus Therapeutic Use

Most Recent Events

02 Jan 2023 New trial record
14 Nov 2022 Primary endpoint (Rate of SLE flares over 24 months) has been met according to Results presented at the ACR Convergence 2022.
14 Nov 2022 Results presented at the ACR Convergence 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com